Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVX 001

Next Previous
Drug Profile

AVX 001

Alternative Names: AKH-217; AVX-001

Latest Information Update: 18 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avexxin
  • Developer Coegin Pharma
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Phase I/II Actinic keratosis
  • Phase I Basal cell cancer

Most Recent Events

  • 18 Dec 2024 Phase-I clinical trials in Basal cell cancer (Topical) (Coegin Pharma pipeline, December 2024)
  • 14 Sep 2022 Coegin Pharma plans a phase IIa trial for Basal cell cancer in first-half of 2023 (Topical) (Coegin Pharma pipeline, September 2022)
  • 03 Jan 2022 Coegin Pharma announces intention to submit Clinical trial application for Basal cell cancer (Topical) in Q1 2022 (Coegin Pharma pipeline, January 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top